Medical Case Reports

An 88-year-old male patient was brought to the emergency department on July 25, 2021, with complaints of shortness of breath, headache, cough, and generalized body weakness. He was screened for SARS-CoV-2, and he tested negative on the rapid antigen test. A subsequent nasopharyngeal swab for the reverse transcription-polymerase chain reaction (RTPCR) test for SARS-CoV-2, however, yielded positive results. He presented with blood pressure (BP) of 136/62 millimeters of mercury (mmHg), a pulse of 113 per minute, oxygen saturation of 52% at room air, a body temperature of 37.3°C, and blood sugar at 6.2 mmol/lite. An examination of the respiratory system revealed coarse crackles with decreased air entry in both lung fields and all other systems were within normal limits. His medical history included diagnosis with benign prostatic hyperplasia (BPH) after a prostate biopsy in 2015. He received the first dose of the Pfizer-BioNTech vaccine on June 8, 2021, and the second dose on July 20, ...

A 50-year-old multiple-sclerosis patient fails to mount a humoral response after the first, second and third Moderna vaccination and even after COVID-19. A 50-year-old female with relapsing remitting multiple sclerosis since 2013, treated with ocrelizumab since 2018, was  vaccinated with Spikevax (Moderna) in April and May 2021  and received the booster vaccination in October. One to two weeks prior to the ocrelizumab infusions in March and September 2021 the patient was B-cell depleted.  Eleven days after the booster vaccination the patient was tested positive for SARS-CoV-2 by PCR. She experienced symptoms of dyspnea and fever and was admitted to the hospital for eleven days where she was treated with oxygen and dexamethasone.  After each vaccination and even  28 days after third vaccination and 17 days after positive SARS-CoV-2 PCR, the patient remained negative for anti-RBD as well as anti-nucleocapsid protein antibodies. The patient fully recovered from COV...

  A 67-year-old physician with a past history of hypertension, allergic rhinitis and hepatic hemangioma for 10 years received the first dose of ChAdOx1nCov-19 vaccine on 2021/3/22. Three days later, he presented with fever, up to 39 o C, combined with general soreness.  His fever subsided after a pain reliever, occurred again 9 days later and subsided again.  Neither leukocytosis nor a higher C-reactive protein (CRP) level was noted at that time, but he developed a fever again two days later and subsequently  tested for  significantly more elevated  inflammatory markers (C RP level of 148.56 mg/L (reference range <5 mg/L) and procalcitonin C of 3.1 ng/ml (reference range <0.5 ng/mL), ALT and AST slightly elevated). His COVID-19 nasopharyngeal swab test was still negative. Both abdominal echography and computed tomography of the abdome n showed abscesses at left lateral segment of the liver. The pus smear revealed Gram-negative bacilli that was la...

  Two weeks after receiving the third injection of the CoronaVac COVID-19 vaccine, a  77-year-old male with eruptive skin lesions was admitted to a clinic in Turkey. He complained of arthralgia, myalgia, and general fatigue and also experienced intestinal symptoms such as bloody diarrhea and abdominal pain. He reported a mildly itchy rash with his first (5 month prior) and second (4 month prior) immunizations, without fever, difficulty breathing, edema, oliguria, or other systemic symptoms.  Dermatologic examination revealed diffuse palpable, tender, non-blanching violaceous coalescent patches on the thighs, calves, feet, and hands. There were also bullous hemorrhagic lesions distributed bilaterally on the extensor sides of the lower legs and feet.  Pathologic laboratory testing revealed elevated C-reactive protein levels of 60 mg/L (normal: 6). D-dimer values and other tests were normal.  Autoimmune workup revealed no pathologic findings. Screenings for vi...

A 90-year old woman weighting 40.5kg (89.3 pounds) develops anorexia after the first dose of the COVID-19 Pfizer vaccine (0.3 ml containing 30μg of mRNA). Vital records showed abrupt increases in the body temperature, systolic and diastolic blood pressure, and pulse, and decreases in the intake of meals and drinks and body weight. The patient lost 1/4 of her body weight by the time of death 28 weeks after the COVID-19 vaccination.  The patient also experienced hallucinations and decreased mental status, as well as decreased SpO 2  levels.  One month before death, her status was changed from level 2 (partial assistance) to level 5 (bedridden).  Before the injection her vitals were steady with exception of short-termed changes because of minor illnesses. Vital records restricted to the last 6 months (180 days;  Figure 2 ) show the pre-injection horizontal regression line, large + level change for temperature, pressures, and pulse, and – level change for meals and ...

An 18-year-old woman started experiencing symptoms 9 days after vaccination.  She checked into the emergency room complaining of severe headaches and extreme light sensitivity. A CT scan and neurological tests found nothing, so doctors discharged her and recommended to return in 15 days for further tests. But she returned to the hospital just two days later. She now suffered from paralysis in at least one part of her body. This time she was diagnosed with  cavernous sinus thrombosis , meaning a blood clot in the space between the eye sockets and brain. It blocked the primary vein between her head and the heart. Doctors also discovered that she had a brain bleed . She underwent two surgeries, one to remove the blood clot and the second to relieve pressure in her head caused by the bleeding. But the damage was done.  She died 5 days later,  She was previously healthy and was not taking any medications.  REFERENCES Camilla, who died at the age of 18 after AstraZene...

An 18-year-old female was admitted to a hospital after she was experiencing 'thunder-clap' headaches,  the "worst headache" she had ever experienced,  two weeks after receiving her first dose of AstraZeneca Covid vaccine. An inquest heard the headaches were the result of thrombosis in her sinus cavity.  Because of her low platelet count, doctors initially ruled out a brain hemorrhage. She suffered all of the "common" side effects of the vaccine but hoped these would last approximately 12 to 18 hours, the inquest heard. But two weeks later she was "screaming in pain" with the "worst headache" she had ever experienced. Despite this, a CT scan was reported as "normal". Three days after her admission, she was administered a dose of platelets and her inquest heard that she began to rapidly deteriorate. She suffered from fits and was "not responding to seizure control", the inquest heard. She was then incubated and put on ...

I n younger men <40 years the risk of myocarditis was shown to be higher after vaccination than SARS-CoV-2 infection.  Between  December  1,  2020,  to  November  15,  2021  a  total  of  42,200,614  people  were  vaccinated  with  at  least  one  dose  of  ChAdOx1  (n=20,646,456),  BNT162b2  (n=20,391,600)  or  mRNA-1273 (n=1,162,558) in England. Of these, 38,347,981 received  two  doses  of  either  ChAdOx1  (n=20,059,058),  BNT162b2  (n=17,294,004)  or  mRNA-1273  (n=1,039,919) and 10,978,507 people received a third dose of ChAdOx1 (n=35,608), BNT162b2  (n=10,599,183)  or  mRNA-1273  (n=343,716).  Amongst  people  receiving  at  least  one  vaccine  dose, 5,185,772 (12.3%) tested positive for SARS-CoV-2; 2,834,579 (54.7%) prior to vacc...

Among the 54 fully vaccinated patients who developed COVID-19 (data from  ClinicalTrials.gov  study NCT04354701 ) , 35 (65%) were hospitalized, 10 (19%) were admitted to ICU or required MV, and 7 (13%) died within 30 days. Comparable rates were observed in the unvaccinated group. The primary endpoint was 30-day all-cause mortality among fully vaccinated patients compared to the unvaccinated population after Inverse Probability of Treatment Weighting (IPTW) to adjust for baseline clinical variables. SFollowing IPTW, t here was no statistical difference in 30-day mortality between the fully vaccinated patients compared to the unvaccinated cohort Adjusted Odds Ratio (AOR) 1·08, 95% CI: 0·41-2·82. Increased 30-day mortality was associated with lymphopenia (AOR 1·68, 95% CI: 1·11-2·55), the presence of comorbid conditions (mCCI of 1 vs 0: AOR 1·66, 95% CI: 1·07-2·59 and mCCI ≥2 vs 0: AOR 2·10, 95% CI: 1·36-3·24), worse performance status (ECOG PS 1 vs 0: AOR 2·26, 95% CI: 1·25-4·06...